(VIANEWS) – The NASDAQ ended the session with argenx SE rising 29.53% to $491.01 on Monday, after two successive sessions in a row of gains. NASDAQ jumped 0.93% to $14,244.95, following the last session’s downward trend on what was a somewhat up trend trading session today.
argenx SE’s last close was $379.08, 10.59% under its 52-week high of $423.99.
About argenx SE
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, argenx SE has a trailing twelve months EPS of $-9.4.
Volatility
argenx SE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.49%, a negative 0.23%, and a positive 1.11%.
argenx SE’s highest amplitude of average volatility was 1.80% (last week), 1.22% (last month), and 1.11% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, argenx SE’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for argenx SE is 1483010 which is 569.06% above its average volume of 221654.
Moving Average
argenx SE’s worth is way higher than its 50-day moving average of $395.72 and way above its 200-day moving average of $378.70.
More news about argenx SE (ARGX).
